Peer-influenced content. Sources you trust. No registration required. This is HCN.

Endocrinology AdvisorBrenzavvy Approved for Adults with Type 2 Diabetes

The SGLT2 inhibitor bexagliflozin is now available under the brand name Brenzavvy. Approval was based on monotherapy trials versus glimepiride, where the new drug was non-inferior, and in combination with metformin.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form